U.S. President Donald Trump signed an executive order aimed at accelerating federal review processes for certain psychedelic substances, including Ibogaine, a drug currently classified among the most restricted substances under U.S. law. The move signals a significant shift in federal policy toward exploring the potential medical uses of psychedelics, particularly for conditions that have proven difficult to treat.
The administration framed the decision as a response to growing interest from veterans’ groups and medical advocates who argue that ibogaine may offer benefits for individuals suffering from disorders such as post-traumatic stress disorder (PTSD) and opioid addiction. During the announcement, Trump said the order could help people with severe symptoms “reclaim their lives” and improve their overall well-being.
Several prominent figures attended the Oval Office event, including Health Secretary Robert F. Kennedy Jr., media personality Joe Rogan, and former Navy SEAL Marcus Luttrell. Luttrell shared personal testimony, stating that ibogaine had a transformative positive impact on his life.
Despite the optimism, the drug carries known risks. Ibogaine has been linked to serious side effects, including potentially fatal heart complications. The National Institutes of Health halted research into the substance in the 1990s due to concerns about cardiovascular toxicity.
Looking ahead, the Food and Drug Administration (FDA) is expected to take steps to accelerate research. Plans include issuing priority review vouchers for three psychedelic substances and allowing the first human clinical trials of ibogaine in the United States.
Overall, the executive order marks a controversial but potentially groundbreaking development in drug policy, balancing hopes for new treatments with ongoing concerns about safety and regulation.
